Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
A Double-blind, Randomized, Placebo-controlled, Phase I , Multiple-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Orally-administered HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease
Sponsor: High Point Pharmaceuticals, LLC.
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from High Point Pharmaceuticals, LLC.
More terminations from High Point Pharmaceuticals, LLC.
Other Mild Alzheimer's Disease trials with similar outcome
A PHASE1 clinical study on Mild Alzheimer's Disease and Mild Cognitive Impairment, this trial is terminated or withdrawn. The trial is conducted by High Point Pharmaceuticals, LLC. and has accumulated 6 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Oct 2011
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- High Point Pharmaceuticals, LLC.
For direct contact, visit the study record on ClinicalTrials.gov .